Yes (Dyazide® strength only)

Antihypertensive Agent, Combination; Diuretic, Potassium Sparing; Diuretic, Thiazide

Management of mild to moderate hypertension; treatment of edema in congestive heart failure and nephrotic syndrome

C

1% to 10%: Gastrointestinal: Loss of appetite, nausea, vomiting, stomach cramps, diarrhea, upset stomach

<1%:

Central nervous system: Dizziness, fatigue

Dermatologic: Purpura, cracked corners of mouth

Endocrine & metabolic: Electrolyte disturbances

Gastrointestinal: Bright orange tongue, burning of tongue

Hematologic: Aplastic anemia, agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenia, megaloblastic anemia

Neuromuscular & skeletal: Muscle cramps

Ocular: Xanthopsia, transient blurred vision

Respiratory: Allergic pneumonitis, pulmonary edema, respiratory distress

Hydrochlorothiazide:

Decreased effect of oral hypoglycemics; decreased absorption with cholestyramine and colestipol

Increased effect with furosemide and other loop diuretics

Increased toxicity/levels of lithium

Triamterene:

Increased risk of hyperkalemia if given together with amiloride, spironolactone, angiotensin-converting enzyme (ACE) inhibitors

Increased toxicity of amantadine (possibly by decreasing its renal excretion)

Protect from light

Competes with aldosterone for receptor sites in the distal renal tubules, increasing sodium, chloride, and water excretion while conserving potassium and hydrogen ions; may block the effect of aldosterone on arteriolar smooth muscle as well

Adults: Oral:

Triamterene/hydrochlorothiazide 75 mg/50 mg: 1/2 -1 tablet daily

Avoid excessive ingestions of foods high in potassium or use of salt substitutes; should be administered after meals

Thiazide diuretics are effective first-line therapeutic agents in the management of hypertension and have proven to be of benefit in terms of cardiovascular outcome. The initial concern about thiazide diuretic-induced hypokalemia, glucose intolerance, and lipid profiles does not appear to be of substantial clinical consequence in the treatment of hypertension. The benefits of this class of agents in the treatment of hypertension is established and compares well with other first-line therapeutic agents. The combination of hydrochlorothiazide and triamterene may reduce the incidence of hypokalemia.

No information available to require special precautions

No effects or complications reported

See individual agents. Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend to get pregnant. Consult prescriber if breast-feeding.

Monitor blood pressure, serum electrolytes, BUN, creatinine, liver function tests, signs of hyperkalemia

Capsule (Dyazide®): Hydrochlorothiazide 25 mg and triamterene 37.5 mg

Tablet:

Maxzide®-25: Hydrochlorothiazide 25 mg and triamterene 37.5 mg

Maxzide®: Hydrochlorothiazide 50 mg and triamterene 75 mg